OssDsign

OssDsign

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

OssDsign - Lower sales but higher gross margin

03 februari 2026

  • 24% organic sales growth in Q4 (ABGSCe +27%)
  • Adj. EBIT -2% vs ABGSCe
  • No change in outlook

Q4 results

OssDsign reported a mixed set of numbers in Q4 with lower sales but higher gross margin and good cost control. Q4 sales came in at SEK 45.1m (-5% vs ABGSCe SEK 47.3m, no consensus) and adj. EBIT of SEK -9.4m, -2% vs ABGSCe of -9.2m. The miss on adj. EBIT is attributable to lower sales as core opex came in better and gross was higher at 96.3% in Q4 (vs ABGSCe 95.5%). We are pleased to see that the 'sales and commission and fees' as percentage of sales continues to come down, was 47.6% in Q4 vs ABGSCe at 51.5%). Q4 reported EBIT was negatively impacted by CEO transition costs of SEK 12m (ABGSCe SEK 0m), booked as NRI. Organic sales growth in Q4 amounted to 24% (ABGSCe 27%).

Webcast at 11.00 CET today, link: https://www.finwire.tv/webcast/ossdsign/q4-2025/

Estimates

Company is not providing any outlook for 2026 or changing its mid-term financial targets of reaching sales of SEK >400m by 2028 and to become cash flow and EBIT positive in the second half of its 'Strategy Period' (2025-2028). Based on the deviation on adj EBIT in Q4, we expect FY'26e adj. EBIT to be revised down by mid- to high single digit.

Share price view

The stock has been soft into Q4, down 2-3% (-5d) and down weak YTD (-15%). Based on the miss on sales and deviation on adj EBIT, we expect to see a small negative share price reaction in similar magnitude as the estimated earnings revisions.



Q4 deviation table
Source: ABG Sundal Collier, Company data

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-03-12 StrongPoint - Investor update StrongPoint Analys
2026-03-08 Medicover - From build-out to fill-up Medicover Analys
2026-03-02 Qben Infra - Portfolio reshaping continues Qben Infra Analys
2026-02-27 Xplora Technologies - Record quarter driven by Se... Xplora Tech.. Analys
2026-02-24 Isofol Medical - From first lessons to second exe... Isofol Medical Analys
2026-02-24 B3 Consulting Group - Cost adjustments should lif... B3 Consulti.. Analys
2026-02-23 Ework Group - Market conditions yet to improve Ework Group Analys
2026-02-23 Formpipe - Good margins, but ACV lags Formpipe Analys
2026-02-23 Energy Save - Back to growth, but softer H1'26 ex... Energy Save Analys
2026-02-23 Fastpartner - Outlook taking a hit Fastpartner Analys
2026-02-23 Cavotec - Industry shines in cautious environment Cavotec Analys
2026-02-20 Arctic Paper - Still challenging Arctic Paper Analys
2026-02-20 Inission - Set for substantial earnings growth Inission Analys
2026-02-20 BTS Group - Ahead of plan on growth recovery BTS Group Analys
2026-02-20 Energy Save - OEM sales up, softer start to '26 e... Energy Save Analys
2026-02-20 Formpipe - Weaker ACV, but higher dividends Formpipe Analys
2026-02-20 B3 Consulting Group - Margin beat on cost cuts B3 Consulti.. Analys
2026-02-20 BTS Group - North America behind Q4 miss BTS Group Analys
2026-02-20 Skolon - Q4'25 momentum to also pay off in H1'26 Skolon Analys
2026-02-20 Ogunsen - Easier comps await in '26e Ogunsen Analys